


Cite this: *RSC Adv.*, 2020, 10, 10584

# Triple-negative breast cancer suppressive activities, antioxidants and pharmacophore model of new acylated rhamnopyranoses from *Premna odorata*†

Abeer H. Elmaidomy,<sup>a</sup> Rabab Mohammed,<sup>a</sup> Asmsaa I. Owis,<sup>a</sup> Mona H. Hetta,<sup>b</sup> Asmaa M. AboulMagd,<sup>c</sup> Abu Bakar Siddique,<sup>d</sup> Usama Ramadan Abdelmohsen,<sup>ef</sup> Mostafa E. Rateb,<sup>ag</sup> Khalid A. El Sayed<sup>d</sup> and Hossam M. Hassan<sup>\*a</sup>

Phytochemical investigation of *Premna odorata* Blanco "Lamiaceae" young stems afforded four new acylated rhamnopyranoses 1–4, along with fourteen known compounds 5–19. The structures of the new compounds were confirmed using extensive 1D, 2D NMR, and HRESIMS analysis. The isolated compounds were tested for their cell proliferation and migration inhibition activities against the invasive human triple-negative breast cancer cells MDA-MB-231 and MCF-7, and the normal human breast cell line MCF-10A. In addition, free radical scavenging activities using 2,2'-diphenyl-1-picrylhydrazyl (DPPH) were studied. Compound 1 was the most active as an antiproliferative agent, showing a high to moderate antiproliferative effect with an IC<sub>50</sub> value of 4.95 and 17.7 μM against MCF-7 and MDA-MB-231, respectively. The antiproliferative activities of compounds 1–5 against the normal breast cell line MCF-10A were moderate to low with IC<sub>50</sub> values of 13.91 to 27.70 μM. On the other hand, compounds 1 and 10 suppressed MDA-MB-231 cell migration in the wound-healing assay at 10 μM concentration. Meanwhile, compounds 1–5 exhibited the highest value of DPPH radical scavenging activities with an IC<sub>50</sub> value range of 17.5–20.43 ± 0.5 μg mL<sup>-1</sup>. The pharmacophore model generated using Molecular Operating Environment (MOE) for compounds 1–5 showed three hydrogen bond acceptors (HBAs), one hydrogen bond donor (HBD), one aromatic ring (Aro), and one hydrophobic (Hyd.) group. The central HBA feature lies at a distance of 4.36 Å and 6.38 Å from the remaining two HBA features. Also, the HBD feature maintains a distance of 2.74 Å from the aromatic feature. Acylated rhamnopyranoses can be considered good scaffolds for developing new anti-breast cancer and antioxidant compounds.

Received 21st February 2020  
Accepted 25th February 2020

DOI: 10.1039/d0ra01697g

rsc.li/rsc-advances

## 1. Introduction

Breast cancer (BC) is the most commonly diagnosed cancer and the second-leading cause of cancer-related death in women worldwide.<sup>1,2</sup> BC is a heterogeneous disease that can be

classified into four major molecular subtypes: luminal A, luminal B, human epidermal growth factor receptor (HER2)-overexpressing, and basal-like, based on clinical, histopathological, and microarray criteria.<sup>1,2</sup> Most BC mortalities are mainly linked to metastatic or recurrent complications.<sup>3</sup>

One of the key processes leading to metastasis of cancer is cancer cell migration.<sup>1</sup> Cancer cells migrate within the primary tumor stroma after invasion to access the circulation and lymphatic system, and metastasize to secondary sites at distant organs. Due to the importance of cancer cell migration for metastasis and subsequent morbidity and mortality, targeting migration is critical for cancer control especially in highly metastatic and recurrent phenotypes (e.g., TNBC characterized by poor progression-free survival).<sup>3,4</sup> Standard chemotherapeutics mainly induce programmed cell death in rapidly dividing cancer cells through mechanisms including the inhibition of cell division and interruption of deoxyribonucleic acid/ribonucleic acid (DNA/RNA) synthesis, but do not necessarily block cell motility. Therefore, residual surviving resistant tumor cells or dormant tumor cells can resist chemotherapy and/or

<sup>a</sup>Department of Pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt. E-mail: hossam.abdelazeem@pharm.bsu.edu.eg

<sup>b</sup>Department of Pharmacognosy, Faculty of Pharmacy, Fayoum University, Fayoum 63514, Egypt

<sup>c</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Nahda University, Beni-Suef 62514, Egypt

<sup>d</sup>School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA

<sup>e</sup>Department of Pharmacognosy, Faculty of Pharmacy, Minia University, Minia 61519, Egypt

<sup>f</sup>Department of Pharmacognosy, Faculty of Pharmacy, Deraya University, Minia 61111, Egypt

<sup>g</sup>School of Computing, Engineering and Physical Sciences, University of the West of Scotland, PA1 2BE Paisley, UK

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ra01697g



radiotherapy, and can be activated and undergo invasion, migration and develop distant metastases.<sup>4</sup>

On the other hand, reactive oxygen species (ROS) are produced by living organisms due to their negative cellular metabolism.<sup>5</sup> At low-to-moderate concentrations, ROS improved physiological cell processes. Conversely, they changed cell components such as lipids, proteins, and deoxyribonucleic acid at high concentrations.<sup>6</sup> ROS are related to almost all aspects of cancer.<sup>6</sup> Consequently, reducing ROS can be correlated to the anticancer effect.<sup>7</sup> Natural antioxidants can eliminate free radicals such as single oxygen or peroxides by donating hydrogen and chelating metal ions. These activities decrease deoxyribonucleic acid damage, reduce lipid peroxidation, and inhibit cell proliferation related to cancer development.<sup>8</sup>

Phenolic natural compounds are distributed in plants, and have gained much attention in recent years because of their antioxidant activity, free radical scavenging ability, antitumor effects, and their proven efficacy and safety.<sup>8,9</sup> Recently, natural products have begun to play an important role in the discovery of anticancer antioxidant lead compounds. About 50% of today's anticancer drugs in clinical practice are either natural products or modeled after parent natural product compounds such as taxanes, doxorubicin, epothilones, vincristine, camptothecin, and several others.<sup>6-9</sup>

Plants of the genus *Premna*, Lamiaceae, are rich resources for the production of diverse bioactive secondary metabolites that have cytotoxic antioxidant activities. For example, the diterpenes latifolionol and dihydrolatifolionol isolated from the bark of *P. latifolia* showed potent cytotoxic activity against HT-29 and the hepatocellular carcinoma (HepG2) cell lines.<sup>10</sup> Also, the leaf extract from *P. odorata* afforded multiple acylated iridoid glycosides and rhamnopyranoses with good antiproliferative and antimigratory activities against triple-negative breast cancer cell lines by targeting the c-Met kinase domain.<sup>11</sup> The flavone glycosides 4'-hydroxy-8,3'-dimethoxy-6-acroleinylflavan-3,4-diol and naringenin isolated from *P. latifolia* leaves significantly inhibited the oxidation of DPPH with a half maximal inhibitory concentration (IC<sub>50</sub>) of 22.5 and 16.0  $\mu\text{g mL}^{-1}$ , respectively.<sup>12</sup> The furofuran lignans (4- $\beta$ -hydroxyasarinin-1- $O$ - $\beta$ -D-glucopyranoside, premnadimer) and iridoid glycosides (premnosidic acid, 10-*O*-*trans*-*p*-coumaroylcatalpol, 10-*O*-*trans*-*p*-coumaroyl-6-*O*- $\alpha$ -L rhamnopyranosyl catalpol, 4''-hydroxy-E-globularinin) were found to contribute to the antioxidant activity of the stem bark of *P. integrifolia* when evaluated with radical scavenging DPPH, nitric oxide (NO) and ferric reducing antioxidant power (FRAP) assays.<sup>13</sup> A recent study also identified the aromatic diterpene 11,12,16-trihydroxy-2-oxo-5-methyl-10-demethyl-abieta-1,<sup>10</sup> and 6,8,11,13-pentene as an antioxidant constituent from *P. serratifolia* with an IC<sub>50</sub> of  $20.4 \pm 1.3 \mu\text{g mL}^{-1}$  towards a DPPH assay.<sup>14</sup> The diterpenoids, icetexanes I and III, and the dimeric diterpene prenalatifolin A isolated from the bark of *P. tomentosa* showed selective inhibitory activity for the growth of the human estrogen-dependent breast cancer Michigan Cancer Foundation-7 (MCF-7) cells and the colorectal cancer human adenocarcinoma colorectal cell line (HT-29) cells.<sup>15,16</sup>

This study reports the isolation of four new acylated rhamnopyranoside esters 1–4, along with several known secondary

metabolites isolated from the young stems of *P. odorata*. A previous successful biological investigation on the acylated rhamnopyranose 1-*O*-*trans*-*p*-coumaroyl-2-*O*-*trans*-caffeoyl- $\alpha$ -L-rhamnopyranose isolated from the leaves of *P. odorata* showed antiproliferative activity, with an IC<sub>50</sub> value of 13.3  $\mu\text{M}$  against MDA-MB-231.<sup>11</sup> This previous report encouraged further biological investigations on the isolated acylated rhamnopyranoside esters from the young stems of *P. odorata* as antiproliferative and antimigratory agents against the invasive human triple-negative breast cancer cells MDA-MB-231, MCF-7, as well as the normal cell line MCF-10A and antioxidant activities.

## 2. Experimental

### 2.1. Plant material

Young stems from *P. odorata* were collected on May 2018 from the Giza Zoo garden, Egypt and identified by Dr Abd El-Halim A. Mohammed, Horticultural Research Institute, Department of Flora and Phytotaxonomy Researches, Dokki, Cairo, Egypt. A voucher specimen (2018-BuPD 46) was deposited at the Department of Pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Egypt.

### 2.2. Chemicals and reagents

The solvents used in this work included *n*-hexane (*n*-hex., boiling point b.p. 60–80 °C), dichloromethane (DCM), ethyl acetate (EtOAc), *n*-butanol (*n*-but.), ethanol (EtOH), methanol (MeOH), formic acid (F.A.), glacial acetic acid (G.A.A.) and sulfuric acid purchased from El-Nasr Company for Pharmaceuticals and Chemicals (Egypt). High Performance Liquid Chromatography (HPLC) and deuterated solvents used for chromatographic and spectroscopic analyses were purchased from Sigma-Aldrich (Saint Louis, Missouri, USA), including HPLC-methanol, HPLC-water, chloroform (CDCl<sub>3</sub>), methanol (CD<sub>3</sub>OD), and dimethyl sulfoxide (DMSO-*d*<sub>6</sub>). Column chromatography (CC) was performed using silica gel 60 (63–200  $\mu\text{m}$ , E. Merck, Sigma-Aldrich), and polyamide-6 (50–160  $\mu\text{m}$ ), while silica gel GF254 for Thin-layer chromatography (TLC) (El-Nasr Company for Pharmaceuticals and Chemicals, Egypt) was employed for vacuum liquid chromatography (VLC). Thin-layer chromatography (TLC) was carried out using pre-coated silica gel 60 GF254 plates (E. Merck, Darmstadt, Germany; 20 × 20 cm, 0.25 mm in thickness). Spots were visualized by spraying with *para*-anisaldehyde (PAA) reagent (85 : 5 : 10 : 0.5 absolute EtOH : sulfuric acid : G.A.A. : *para*-anisaldehyde), followed by heating at 110 °C.<sup>17</sup> For the biological study, DPPH and L-ascorbic acid were purchased from (Sigma-Aldrich, Saint Louis, Missouri, USA).

### 2.3. Spectral analyses

Proton <sup>1</sup>H and Distortionless Enhancement by Polarization Transfer-Q (DEPT-Q) <sup>13</sup>C NMR spectra were recorded at 400 and 100 MHz, respectively. Tetramethylsilane (TMS) was used as an internal standard in chloroform (CDCl<sub>3</sub>), methanol (CD<sub>3</sub>OD), and dimethyl sulfoxide (DMSO-*d*<sub>6</sub>), using the residual solvent peak ( $\delta_{\text{H}} = 7.26$  and  $\delta_{\text{C}} = 77.0$ ), ( $\delta_{\text{H}} = 3.34$ , 4.78 and  $\delta_{\text{C}} = 49.9$ )



and ( $\delta_{\text{H}} = 2.50$  and  $\delta_{\text{C}} = 39.5$ ) as references, respectively. Measurements were performed on a Bruker Advance III 400 MHz with BBFO Smart Probe and a Bruker 400 MHz EON Nitrogen-Free Magnet (Bruker AG, Billerica, MA, USA). Carbon multiplicities were determined using a DEPT-Q experiment. The optical rotation in methanol was obtained using a Perkin-Elmer 343 polarimeter (PerkinElmer Inc., Waltham, MA, USA). The ultraviolet radiation (UV) spectrum in methanol was obtained using a Shimadzu UV 2401PC spectrophotometer (Shimadzu Corporation – UV-2401PC/UV-2501PC, Kyoto, Japan). Infrared (IR) spectra were measured using a Jasco FTIR 300E infrared spectrophotometer. HRESIMS data were obtained using an Acquity Ultra Performance Liquid Chromatography system coupled to a Synapt G2 HDMS quadrupole time-of-flight hybrid mass spectrometer (Waters, Milford, MA, USA). HPLC chromatographic separations were conducted using an Agilent 1260 Infinity preparative pump (G1361A), Agilent 1260 diode array detector VL (G1315 D), Agilent 1260 Infinity Thermostand column compartment (G1361 A), Agilent 1260 Infinity preparative autosampler (G2260A) and a YMC-Pack ODS-A A-324 column (i.d.  $10 \times 300$  mm, YMC, Kyoto, Japan).

#### 2.4. Extraction and fractionation of plant material

The young stems (5 kg) were collected and air-dried in the shade for one month. After drying, the young stems were finely powdered using an OC-60B/60B set small corn bark grinding machine for herbs (60–120 mesh, Henan, Mainland China). The finely powdered young stems were extracted by maceration without agitation using 70% ethanol (5 L,  $3 \times$ , seven days each) at room temperature, and concentrated under vacuum at  $45^\circ\text{C}$  using a rotary evaporator (Buchi Rotavapor R-300, Cole-Parmer, Vernon Hills, IL, USA) to afford 150 g crude extract. The dry extract was suspended in 300 mL distilled water ( $\text{H}_2\text{O}$ ), and successively portioned with solvents of different polarities (*n*-Hex., DCM, EtOAc, and *n*-but.). The organic phase in each step separately evaporated under reduced pressure to afford the corresponding fractions I (8.0 g), II (8.0 g), III (10.0 g) and IV (50.0 g), respectively, while the remaining mother liquor was then concentrated down to give the aqueous fraction (V). All resulting fractions were kept at  $4^\circ\text{C}$  for biological and phytochemical investigations.

#### 2.5. Isolation and purification of compounds

A part of fraction I (5 g) was subjected to VLC fractionation using silica gel GF<sub>254</sub> (column  $6 \times 30$  cm, 50 g). Elution was performed using *n*-hex. : EtOAc gradient mixtures in order of increasing polarities (0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 80 and 100%, 1 L each, flow rate (FR)  $3 \text{ mL min}^{-1}$ ), then with DCM : EtOAc (50, 50, 1 L, FR  $3 \text{ mL min}^{-1}$ ), and finally with EtOAc. The effluents from the column were collected in fractions (100 mL each); and each collected fraction was concentrated and monitored by TLC using the system *n*-hex. : EtOAc 8 : 2 and PAA reagent. Similar fractions were grouped and concentrated under reduced pressure to provide three sub-fractions (I<sub>1</sub>–I<sub>3</sub>). Crystallization of sub-fractions I<sub>1</sub> and I<sub>3</sub> was performed separately using MeOH, and afforded compounds **10**

(16 mg) and **18** (30 mg), respectively. Subfraction I<sub>2</sub> (1.0 g) was further fractionated on a silica gel 60 column. An elution was performed using *n*-hex. : EtOAc gradient mixtures in order of increasing polarities (0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 80 and 100%, 250 mL each, FR  $3 \text{ mL min}^{-1}$ ). The effluents were collected in fractions (20 mL each); each fraction was concentrated and monitored by TLC to afford compounds **13** (10 mg), **14** (40 mg), and **16** (10 mg).

Fraction II (8 g) was subjected to VLC fractionation on a silica gel (column  $6 \times 30$  cm, 50 g). Elution was performed using DCM : EtOAc gradient mixtures in the order of increasing polarities (0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 80 and 100%, 1 L each, FR  $3 \text{ mL min}^{-1}$ ), then with EtOAc : MeOH (50, 50, 1 L, FR  $3 \text{ mL min}^{-1}$ ), and finally with MeOH. The effluents were collected in fractions (100 mL each); each fraction was concentrated and monitored by TLC using the system DCM : EtOAc 8 : 2 and PAA reagent. Similar fractions were grouped and concentrated under reduced pressure to provide three sub-fractions (II<sub>1</sub>–II<sub>3</sub>). Subfraction II<sub>1</sub> (1 g) was further fractionated on a silica gel column ( $65 \times 1.5$  cm, 50 g), and an elution was performed using *n*-hex. : EtOAc gradient mixtures in order of increasing polarities (0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 80 and 100%, 250 mL each, FR  $3 \text{ mL min}^{-1}$ ). The effluents were collected in fractions (20 mL each); each fraction was concentrated and monitored by TLC to afford compounds **11** (16 mg) and **17** (7 mg). Subfraction II<sub>2</sub> (0.5 g) was further fractionated on silica gel 60 ( $100 \times 1$  cm, 25 g). Elution was performed using DCM : EtOAc isocratic mixture (20%, 500 mL, FR  $3 \text{ mL min}^{-1}$ ) to afford compound **15** (16 mg). Finally, the crystallization of subfraction II<sub>3</sub> from MeOH afforded compound **12** (6 mg).

Moreover, part of the EtOAc fraction III (8 g) was fractionated on a polyamide-6 (column  $50\text{--}160 \mu\text{m}$ ,  $1000 \times 5$  cm, 100 g) using gradient elution, starting with water ( $\text{H}_2\text{O}$ ) and ending with MeOH in the order of increasing polarities (0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 80 and 100%, 1000 mL each, FR  $5 \text{ mL min}^{-1}$ ). The effluents were collected in fractions (200 mL each); each fraction was concentrated and monitored by TLC using system EtOAc : G.A.A. : F.A. :  $\text{H}_2\text{O}$  10 : 1 : 1 : 2 and PAA reagent. Similar fractions were grouped and concentrated under reduced pressure to also provide three sub-fractions (III<sub>1</sub>–III<sub>3</sub>).

Sub-fractions III<sub>1-3</sub> (1.0 g) were separately further fractionated on a silica gel (column  $63\text{--}200 \mu\text{m}$ ,  $65 \times 1.5$  cm, 50 g). Elution was performed using DCM : MeOH gradient mixtures in order of increasing polarities (0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 80 and 100%, 250 mL each, FR  $3 \text{ mL min}^{-1}$ ). The effluents were collected in fractions (20 mL each); each fraction was concentrated and monitored by TLC using system EtOAc : G.A.A. : F.A. :  $\text{H}_2\text{O}$  10 : 1 : 1 : 2 and PAA reagent to afford one promising sub-subfraction III<sub>1-3</sub> (80, 30, 50 mg, respectively), which was further purified in preparative TLC eluted with system EtOAc : G.A.A. : F.A. :  $\text{H}_2\text{O}$  10 : 1 : 1 : 2 to give compounds **1** (6 mg), **2** (7 mg), **3** (6 mg), **4** (7 mg), **5** (7 mg), **6** (5 mg), **7** (6 mg), **8** (6 mg), and **9** (7 mg).

**2.5.1. 1,2-Di-O-trans-p-coumaroyl- $\alpha$ -l-rhamnopyranose (1).** Pale yellow amorphous solid;  $[\alpha]_{\text{D}}^{25} + 35.1$  ( $c$  0.05, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  (log<sub>e</sub>) 214 (sh), 225 (5.5), 260 (2.2), 320 (4.5), 342



(6.0) nm; IR  $\nu_{\max}$  (KBr) 3429, 2926, 1604, 1513, 1259, 1695, 1625, 1167, 1056, 835, 601  $\text{cm}^{-1}$ ; NMR data; see Table 1; HRESIMS  $m/z$  457.1494  $[\text{M} + \text{H}]^+$  (calc. for  $\text{C}_{24}\text{H}_{25}\text{O}_9$ , 457.1499).

**2.5.2. 1,3-Di-O-*trans-p*-coumaroyl- $\alpha$ -L-rhamnopyranose (2).** Pale yellow amorphous solid;  $[\alpha]_{\text{D}}^{25} +35.3$  ( $c$  0.05, MeOH); UV (MeOH)  $\lambda_{\max}$  ( $\log_{\epsilon}$ ) 216 (sh), 230 (5.4), 264 (2.3), 325 (4.7), 342 (6.0) nm; IR  $\nu_{\max}$  (KBr) 3429, 2926, 1604, 1513, 1259, 1695, 1625, 1167, 1056, 835, 601  $\text{cm}^{-1}$ ; NMR data; see Table 1; HRESIMS  $m/z$  457.1496  $[\text{M} + \text{H}]^+$  (calc. for  $\text{C}_{24}\text{H}_{25}\text{O}_9$ , 457.1499).

**2.5.3. 1,2-Di-O-*trans-p*-caffeoyl- $\alpha$ -L-rhamnopyranose (3).** Pale yellow amorphous solid;  $[\alpha]_{\text{D}}^{25} +33.4$  ( $c$  0.05, MeOH); UV (MeOH)  $\lambda_{\max}$  ( $\log_{\epsilon}$ ) 214 (sh), 225 (5.8), 245 (2.2), 280 (5.7), 342 (6.0) nm; IR  $\nu_{\max}$  (KBr) 3421, 2924, 1695, 1629, 1513, 1263, 1695, 1625, 1167, 1060, 833, 601  $\text{cm}^{-1}$ ; NMR data; see Table 1; HRESIMS  $m/z$  489.1395  $[\text{M} + \text{H}]^+$  (calc. for  $\text{C}_{24}\text{H}_{25}\text{O}_{11}$ , 489.1391).

**2.5.4. 1,3-Di-O-*trans-p*-caffeoyl- $\alpha$ -L-rhamnopyranose (4).** Pale yellow amorphous solid;  $[\alpha]_{\text{D}}^{25} +33.1$  ( $c$  0.05, MeOH); UV (MeOH)  $\lambda_{\max}$  ( $\log_{\epsilon}$ ) 214 (sh), 228 (5.8), 245 (2.2), 283 (5.7), 341 (6.0) nm; IR  $\nu_{\max}$  (KBr) 3421, 2924, 1695, 1629, 1513, 1263, 1695, 1625, 1167, 1060, 833, 601  $\text{cm}^{-1}$ ; NMR data; see Table 1; HRESIMS  $m/z$  489.1389  $[\text{M} + \text{H}]^+$  (calc. for  $\text{C}_{24}\text{H}_{25}\text{O}_{11}$ , 489.1391).

## 2.6. Cell lines, culture conditions, and cell viability assessments

The human triple-negative breast cancer cell line MDA-MB-231 was purchased from the American Type Culture Collection (ATCC, Manassas, VA). This cancer cell line was maintained in RPMI-1640 (Gibco® by Life Technologies, Grand Island, NY), which was supplemented with 10% fetal bovine serum (Gemini Bio-Products), 100 U  $\text{mL}^{-1}$  penicillin G, 100  $\mu\text{M}$   $\text{mL}^{-1}$

**Table 1**  $^{13}\text{C}$  and  $^1\text{H}$  NMR data of compounds 1–4<sup>a</sup>

Moietly	Position	1		2		3		4	
		$\delta_{\text{C}}$	$\delta_{\text{H}}$ ( $J$ in Hz)	$\delta_{\text{C}}$	$\delta_{\text{H}}$ ( $J$ in Hz)	$\delta_{\text{C}}$	$\delta_{\text{H}}$ ( $J$ in Hz)	$\delta_{\text{C}}$	$\delta_{\text{H}}$ ( $J$ in Hz)
$\alpha$ -L-Rhamn.	1, CH	91.9	5.18, d (1.6)	94.4	5.13, d (1.6)	91.9	5.18, d (1.6)	94.4	5.13, d (1.6)
	2, CH	73.7	5.19, m	69.7	4.12, dd (2.0, 3.6)	73.7	5.18, m	69.6	4.12, dd (2.0, 3.6)
	3, CH	69.1	4.11, dd (3.6, 9.4)	74.1	5.24, dd (3.6, 9.4)	69.0	4.11, dd (3.6, 9.4)	73.9	5.24, dd (3.6, 9.4)
	4, CH	73.2	3.62, t (9.4)	70.4	3.76, t (9.4)	73.1	3.62, t (9.4)	70.4	3.76, t (9.4)
	5, CH	68.2	3.99, m	68.1	3.95, m	68.1	3.99, m	68.0	3.95, m
	6, CH <sub>3</sub>	17.0	1.34, d (6.0)	17.0	1.33, d (6.0)	17.0	1.34, d (6.0)	17.0	1.33, d (6.0)
<i>trans-p</i> -Coun.	1', qC	125.9		125.9					
	2'/6', CH	130.0	7.41, d (8.0)	130.0	7.39, d (8.0)				
	3'/5', CH	115.6	6.83, d (8.0)	115.6	6.81, d (8.0)				
	4', qC	159.6		159.6					
	7', CH	145.6	7.41, d (16.0)	145.9	7.56, d (16.0)				
	8', CH	113.7	6.37, d (16.0)	113.7	6.28, d (16.0)				
	9', qC	167.7		167.7					
	1', qC	126.0		126.0					
<i>trans-p</i> -Coun.	2'/6', CH	130.1	7.69, d (8.0)	130.1	7.39, d (8.0)				
	3'/5', CH	115.6	6.83, d (8.0)	115.6	6.81, d (8.0)				
	4', qC	159.7		159.7					
	7', CH	145.9	7.64, d (16.0)	146.2	7.66, d (16.0)				
	8', CH	114.1	6.44, d (16.0)	114.2	6.37, d (16.0)				
	9', qC	167.9		167.9					
	1'', qC					126.3		126.3	
	2'', CH					114.0	7.08, d (2.4)	114.0	7.08, d (2.4)
<i>trans</i> -Caff.	3'', qC					148.3		148.3	
	4'', qC					145.4		145.4	
	5'', CH					115.1	6.81, d (8.0)	115.1	6.81, d (8.0)
	6'', CH					121.6	6.91, dd (2.4, 8.0)	121.6	6.91, dd (2.4, 8.0)
	7'', CH					145.7	7.57, d (16.0)	145.7	7.58, d (16.0)
	8'', CH					113.6	6.31, d (16.0)	113.6	6.35, d (16.0)
	9'', qC					167.6		167.6	
	1'', qC					126.3		126.3	
<i>trans</i> -Caff.	2'', CH					114.0	7.08, d (2.4)	114.0	7.08, d (2.4)
	3'', qC					148.3		148.3	
	4'', qC					146.0		146.0	
	5'', CH					115.1	6.81, d (8.0)	115.1	6.81, d (8.0)
	6'', CH					121.7	6.91, dd (2.4, 8.0)	121.7	6.91, dd (2.4, 8.0)
	7'', CH					145.7	7.57, d (16.0)	145.7	7.58, d (16.0)
	8'', CH					113.8	6.33, d (16.0)	113.8	6.42, d (16.0)
	9'', qC					167.7		167.7	

<sup>a</sup> In  $\text{CD}_3\text{OD}$ , 400 MHz for  $^1\text{H}$  and 100 MHz for  $^{13}\text{C}$  NMR;  $J$  in Hz. Carbon multiplicities were determined by DEPT-Q experiments. qC = quaternary, CH = methine, CH<sub>2</sub> = methylene, CH<sub>3</sub> = methyl carbons,  $\alpha$ -L-Rhamn.:  $\alpha$ -L-rhamnopyranoside, *trans-p*-Coun.: *trans-p*-coumaroyl moiety, *trans*-Caff.: *trans*-caffoyl moiety.





streptomycin, and 2 mmol L<sup>-1</sup> glutamine. MCF-7 and MCF-10A cell lines were obtained from American Type Culture Collection, and the cells were cultured using DMEM (Invitrogen/Life Technologies) supplemented with 10% FBS (Hyclone), 10 µg mL<sup>-1</sup> of insulin (Sigma), and 1% penicillin–streptomycin.

The cells were subcultured upon attaining 80% confluence. The cells were maintained at 37 °C in a humidified incubator under 5% CO<sub>2</sub>. A stock solution was prepared by dissolving each tested compound in sterilized DMSO solvent at concentration of 10 mM for all assays. The working solutions at their final concentrations for each assay was prepared in an appropriate culture medium immediately before use. The vehicle DMSO control was prepared by adding the maximum volume of DMSO, which was used in preparing test compounds to the media type such that the final DMSO concentration maintained as the same in the all treatment groups within an experiment and never exceeded 0.1%. (–)Oleocanthal used in all experiments as a positive control based on earlier studies.<sup>18</sup> A viable cell count was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. The optical density of each sample was measured at 570 nm on a Synergy 2-micro-plate reader (BioTek, VT, USA). The number of cells per well was calculated against a standard curve, which was prepared at the start of each experiment by plating various concentrations of cells (1000–60 000 cells per well), as determined using a hemocytometer.

## 2.7. Cell proliferation assay

Proliferation inhibition activities of the free hydroxyl phenolic and/or carboxylic acid groups containing compounds (acylated rhamnopyranoses **1–4**, verbascoside **5**, premnoside E–F **6–7**, oleanolic acid **10**, and maslinic acid **12**) were tested against the invasive human triple-negative breast cancer cells MDA-MB-231, MCF-7 and normal MCF-10A cell lines.<sup>19,20</sup> Cell proliferation was evaluated in the celllines by the MTT assay in triplicate. In brief, breast cells in exponential growth were seeded at a density of 1 × 10<sup>4</sup> cells per well (6 wells per group) in 96-well culture plates and maintained in RPMI-1640 media supplemented with 10% fetal bovine serum. These cells were treated for 24 h with isolated compounds using 10 µM MTT, and allowed to adhere overnight at 37 °C under 5% CO<sub>2</sub> in a humidified incubator.<sup>19</sup> One day later, cells were washed with phosphate-buffered saline, followed by division into different treatment groups. The cells were then fed with serum-free defined RPMI-1640 media and experimental treatments containing designated concentrations of each tested compound or vehicle-treated control media, and incubation resumed at 37 °C under 5% CO<sub>2</sub> for 48 h. The control and treatment media were then removed and replaced with fresh media, and 50 µL of fresh MTT solution (1 mg mL<sup>-1</sup>) was added to each well, and the plates were re-incubated for 4 h at 37 °C. The color reaction was stopped by removing the media and adding 100 µL DMSO in each well to dissolve the formed formazan crystals. The incubation at 37 °C was resumed for up to 20 min to ensure complete dissolution of crystals. The absorbance was determined at λ<sub>570</sub> (nm) using an ELISA plate microreader (BioTek,

Winooski, VT, USA). The % of the cell survival was calculated as follows:

$$\% \text{ cell survival} = \frac{\text{cell no. treatment}}{\text{cell no. DMSO}} \times 100$$

## 2.8. Cell migration assay

Migration inhibition activities of the free hydroxyl phenolic and/or carboxylic acid groups containing compounds (acylated rhamnopyranoses **1–4**, verbascoside **5**, premnoside E–F **6–7**, oleanolic acid **10**, and maslinic acid **12**) were tested against the invasive human triple-negative breast cancer cells MDA-MB-231, MCF-7 and normal MCF-10A.<sup>19,20</sup> Breast cells were plated in sterile 24-well plates and allowed to form a confluent monolayer/well overnight.<sup>19,20</sup> The wounds were then inflicted in each cell monolayer using a sterile 200 µL pipette tip, the media was then removed, and the cells were washed twice using phosphate-buffered saline followed by fresh RPMI medium to remove cell debris. Each test compound concentration (10 µM) prepared in fresh serum-free defined media contained 40 µg mL<sup>-1</sup> Hepatocyte growth factor (HGF) as a mitogen source was added to the wells in triplicate. The cells were incubated for 24 h and then the medium was removed. The cells were washed, fixed, and stained using Giemsa stain. The wound healing was visualized at 0 and 24 h by a Nikon ECLIPSE TE200-U microscope, and the digital images were captured using Nikon NIS Elements software (Nikon Instruments Inc., Melville, NY). The distance traveled by the cells was determined by measuring the wound width after 24 h. The percentages of the cell migration were calculated using the following formula:

$$\% \text{ cell migration} = \frac{T_0 - T_t - \text{TDMSO}}{T_0 - \text{TDMSO}} \times 100$$

where  $T_0$  was the wound thickness at time zero, TDMSO was the wound thickness in the DMSO-treated control wells, while  $T_t$  was the wound thickness in the treated wells.

## 2.9. DPPH radical scavenging activity assay

The radical scavenging activity of the free hydroxyl phenolic and/or carboxylic acid groups containing compounds (acylated rhamnopyranoses **1–4**, verbascoside **5**, premnoside E–F **6–7**, oleanolic acid **10**, and maslinic acid **12**) were tested using the stable radical DPPH assay.<sup>21</sup> In a brief manner, a 1 mL solution of the tested compounds at different concentrations (2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 40, 60, 80, 100 µg mL<sup>-1</sup> in absolute ethanol) was mixed with 2 mL of the freshly prepared DPPH solution (20 µg mL<sup>-1</sup> in absolute ethanol), followed by incubation at room temperature in the dark for 30 min. The absorbance was measured at λ<sub>517</sub> (nm) using a UV-Vis Jenway 6003 spectrophotometer. Ascorbic acid was used as a positive control, and absolute ethanol was used as a blank. The DPPH radical scavenging activity was calculated according to the following equation:

$$\% \text{DPPH scavenging activity} = \frac{A_0 - A_1}{A_0} \times 100$$



where  $A_0$  is the absorbance of the blank and  $A_1$  is the absorbance in the presence of the tested compound or standard.

### 2.10. Pharmacophore model generation

From the previous DPPH results, ChemBioDraw Ultra 12.0 (CambridgeSoft, 100 Cambridge Park Drive, Cambridge, MA 02140) was used to sketch the 2D chemical structures of compounds 1–5 (acylated rhamnopyranoses 1–4, and verbascoside 5), saved in the MDL-molfile format and a conformational training dataset of compounds 1–5 was implemented in Molecular Operating Environment (MOE) (Chemical Computing Group software, Canada) to generate the pharmacophore hypotheses. These were converted to 3D structures and their energies were minimized with the Merck Molecular Force Field (MMFF), using an energy threshold value of 15 kcal mol<sup>−1</sup> above the global energy minimum until a local energy minimum was reached. MOE 2019 was used to generate the pharmacophore models for the aligned molecules using common features for the pharmacophore generation.<sup>22</sup> The 3D space of the pharmacophore sites of a ligand are demonstrated by a set of points. During the pharmacophore hypothesis generation, all compounds were selected with common features such as HBDS, HBAs, ring aromatics (Aro), and hydrophobic groups (Hyd). A scoring function was employed for examining the different pharmacophore hypotheses produced so that the best alignment of the ligands would be produced. Finally, molecular sequence and lowest Root Mean Square Deviation (RMSD) were used as a base to select the developed pharmacophore model (see Table 2).<sup>23</sup>

### 2.11. Statistical analysis

All *in vitro* experiments were performed in triplicate. Pooled data were presented as the mean ± standard error of the mean (SEM) of at least three independent experiments. The differences among various treatment groups were determined by ANOVA, followed by Dunnett's test using PASW Statistics® version 18 (Quarry Bay, Hong Kong). A difference of  $p < 0.05$  was considered statistically significant compared with a vehicle-treated control group and shown by a \* symbol. The IC<sub>50</sub> values were determined using a nonlinear regression curve fitting analysis using GraphPad Prism software version 6 (La Jolla, CA, USA).

**Table 2** Lowest root mean square deviation (RMSD) values used as a base to select the developed pharmacophore model for compounds 1–5<sup>a</sup>

Compound no.	RMSD
1	0.416
2	0.417
3	0.432
4	0.474
5	0.365

<sup>a</sup> RMSD: lowest root mean square deviation.

## 3. Results and discussion

### 3.1. Phytochemical investigation of *P. odorata* young stems

Based on the physicochemical and chromatographic properties, the spectral analyses from UV, <sup>1</sup>H, and DEPT-Q NMR, as well as comparisons with the literature and some authentic samples, the crude ethanolic extract of *P. odorata* young stems afforded the new acylated rhamnopyranoside esters 1–4, along with the known verbascoside 5 (ref. 24) and premnoside E–H 6–9.<sup>11</sup> Additionally, oleanolic acid 10,<sup>25</sup> oleanolic acid methyl ester 11,<sup>26</sup> maslinic acid 12,<sup>25</sup> β-amyryn 13,<sup>27</sup> β-sitosterol 14,<sup>28</sup> daucosterol 15,<sup>29</sup> citrostadienol 16,<sup>30</sup> palmitic acid 17,<sup>31</sup> and tricosane-1-ol 18,<sup>32</sup> were identified (Fig. 1). All characterized compounds (11, 12, and 16) were isolated herein for the first time from the genus *Premna*.

Analysis of the HRESIMS, 1D and 2D NMR data of compounds 1–4 suggested a possible acylated rhamnopyranoside core scaffold.<sup>11</sup> The HRESIMS data for compound 1 showed an adduct pseudo-molecular ion peak at  $m/z$  457.1494 [M + H]<sup>+</sup>, (calc. for C<sub>24</sub>H<sub>25</sub>O<sub>9</sub>, 457.1499), suggesting 13 degrees of unsaturation. The <sup>1</sup>H and DEPT-Q <sup>13</sup>C NMR data (Table 1, Fig. S2–S3†), along with the Heteronuclear Single Quantum Correlation (HSQC) data (Fig. S4†), suggested that six characteristic resonances appeared: five oxymethine groups at δ<sub>H</sub> 5.18 (1H, d,  $J$  = 1.6) δ<sub>C</sub> 91.1, δ<sub>H</sub> 5.18 (1H, m) δ<sub>C</sub> 73.7, δ<sub>H</sub> 4.11 (1H, dd,  $J$  = 3.6, 9.4) δ<sub>C</sub> 69.1, δ<sub>H</sub> 3.62 (1H, t,  $J$  = 9.4) δ<sub>C</sub> 73.2, and δ<sub>H</sub> 3.99 (1H, m) δ<sub>C</sub> 68.2, and one methyl group at δ<sub>H</sub> 1.34 (1H, d,  $J$  = 6) δ<sub>C</sub> 69.1, suggesting the characteristic core structure for a disubstituted α-L-rhamnopyranoside unit.<sup>11</sup> NMR data also showed eight aromatic methine groups at δ<sub>H</sub> 7.41 (2H, d,  $J$  = 8) δ<sub>C</sub> 130.0, δ<sub>H</sub> 6.83 (2H, d,  $J$  = 8) δ<sub>C</sub> 115.6, δ<sub>H</sub> 7.69 (2H, d,  $J$  = 8) δ<sub>C</sub> 130.1, δ<sub>H</sub> 6.83 (2H, d,  $J$  = 8) δ<sub>C</sub> 115.6, four *trans*-olefinic methine groups at δ<sub>H</sub> 7.41 (1H, d,  $J$  = 16) δ<sub>C</sub> 145.6, δ<sub>H</sub> 6.37 (1H, d,  $J$  = 16) δ<sub>C</sub> 113.7, δ<sub>H</sub> 7.64 (1H, d,  $J$  = 16) δ<sub>C</sub> 145.9, δ<sub>H</sub> 6.44 (1H, d,  $J$  = 16) δ<sub>C</sub> 114.1, and six quaternary carbons at δ<sub>C</sub> 125.9, 126.0, 159.6, 159.7, 167.7 and 167.9. These signals are suggestive characteristics for two *trans*-*p*-coumaroyl moieties.<sup>11</sup> The Homonuclear Correlation Spectroscopy (<sup>1</sup>H–<sup>1</sup>H COSY) data of 1 (Fig. 2) confirmed the expected coupling of the oxymethines and methyl H-1–H<sub>3</sub>–6. Moreover, the Heteronuclear Multiple-Bond Correlation (HMBC) experiment showed the <sup>3</sup>J-HMBC correlation of the proton H-1 δ<sub>H</sub> 5.18 (δ<sub>C</sub> 91.1) with the quaternary carbonyl carbon C-9' (δ<sub>C</sub> 167.7) and the <sup>3</sup>J-HMBC correlations of the proton H-2 δ<sub>H</sub> 5.18 (δ<sub>C</sub> 73.7) with the quaternary carbonyl carbon C-9'' (δ<sub>C</sub> 167.9), confirming the connections of the two *trans*-*p*-coumaroyl moieties at C-1 and C-2 of the α-L-rhamnopyranosyl moiety (Fig. 2). The structure of compound 1 was very similar to the known related 1-*O*-*trans*-*p*-coumaroyl-2-*O*-*trans*-caffeoyl-α-L-rhamnopyranose, previously isolated from *P. odorata* leaves,<sup>11</sup> with the replacement of the C-2 caffeoyl ester by a C-2 *p*-coumaroyl ester moiety. This change induced an upfield chemical shift of carbons C-2'', C-4'' and C-6'' in the known C-2 caffeoyl α-L-rhamnopyranose by Δδ<sub>C</sub> −15.9, −14.6 and −8, respectively, while carbon C-3'' was downfield shifted by Δδ<sub>C</sub> +32.4, as compared to those of compound 1. Accordingly, compound 1 was identified as 1,2-di-*O*-*trans*-*p*-coumaroyl-α-L-rhamnopyranose.






Fig. 1 Chemical structure of compounds 1–18 isolated from *Premna odorata* young stems extract.

The molecular formula of compound 2 was identical to that of 1 based on HRESIMS ( $C_{24}H_{25}O_9$ ). The  $^1H$  and  $^{13}C$  NMR data was also very close to those of compound 1 for the two *trans*-*p*-coumaric acid moieties, but differed in the resonated chemical shifts of the oxymethine groups of the core  $\alpha$ -L-rhamnopyranosyl moiety. This suggested a positional difference of the location of the two *trans*-*p*-coumaroyl moieties in the  $\alpha$ -L-rhamnopyranosyl moiety *versus* 1 (Table 1, Fig. 2, and S8–S9†). The assignment of the location of the two *trans*-*p*-coumaric acid moieties in 2 was aided by the HMBC experiment. A  $^3J$ -HMBC correlation of the compound 2 proton H-1 ( $\delta_H$  5.13 ( $\delta_C$  94.4) with the quaternary carbonyl carbon C-9' ( $\delta_C$  167.7) and a  $^3J$ -HMBC correlation of the proton H-3 ( $\delta_H$  5.24 ( $\delta_C$  74.1) with the carbonyl carbon C-9'' ( $\delta_C$  167.9) confirmed the location of the two *trans*-*p*-coumaric moieties at carbons C-1 and C-3 of the  $\alpha$ -L-rhamnopyranosyl moiety. The  $^1H$ - $^1H$  COSY data of 2 (Fig. 2) confirmed the coupling of the oxymethine H-1 ( $\delta_H$  5.13) with H-2 ( $\delta_H$  4.12),

which in turn coupled with H-3 ( $\delta_H$  5.24). This data further validated the 1,3-disubstituted *trans*-*p*-coumaroyl- $\alpha$ -L-rhamnopyranose identity of 2. Comparing the DEPT-Q  $^{13}C$  NMR data of compound 2 with those of 1 showed a downfield shifting of carbons C-1 and C-3 ( $\Delta\delta_C$  +2.5 and +4.9, respectively), while carbons C-2 and C-4 were upfield shifted ( $\Delta\delta_C$  +4.0 and 2.8, respectively) compared with those of compound 1 (Table 1, Fig. 1). Accordingly, compound 2 was identified as 1,3-di-*O*-*trans*-*p*-coumaroyl- $\alpha$ -L-rhamnopyranose.

Compound 3 showed an adduct molecular ion peak at  $m/z$  489.1395  $[M + H]^+$  (calc. for  $C_{24}H_{25}O_{11}$ , 489.1391), which was 32 mass units higher than compounds 1 and 2 and also suggested 13 degrees of unsaturation. The  $^1H$  and  $^{13}C$  NMR data (Table 1, Fig. S14–S15†) suggested six characteristic resonances for a disubstituted  $\alpha$ -L-rhamnopyranoside unit (Table 1, Fig. 2). NMR data also showed six aromatic methine groups at  $\delta_H$  7.08 (2H, d,  $J = 2.4$ )  $\delta_C$  114.0,  $\delta_H$  6.81 (2H, d,  $J = 8$ )  $\delta_C$  115.1,  $\delta_H$  6.91






Fig. 2 Selected HMBC (—) and  $^1\text{H}$ - $^1\text{H}$  COSY (—) correlations of compounds 1–4.

(2H, dd,  $J = 2.4, 8$ )  $\delta_{\text{C}}$  121.6, 121.7, four *trans*-olefinic methine groups at  $\delta_{\text{H}}$  7.57 (2H, d,  $J = 16$ )  $\delta_{\text{C}}$  145.7,  $\delta_{\text{H}}$  6.31, 6.33 (2H, d,  $J = 16$ )  $\delta_{\text{C}}$  113.6, 113.8, and eight quaternary carbons at  $\delta_{\text{C}}$  126.3, 126.3, 148.3, 145.4, 146, 148.3, 176.6 and 167.7, which suggested two possible *trans*-caffeic acid moieties.<sup>16</sup> The additional oxygen in each caffeic acid moiety justified the additional 32 mass units increase observed for compound 3 *versus* compounds 1 and 2. The  $^1\text{H}$ - $^1\text{H}$  COSY data of 3 (Fig. 2), was similar to that of 1 for the 1,2-disubstituted  $\alpha$ -L-rhamnopyranoside unit. Moreover, the  $^3J$ -HMBC correlation of H-1  $\delta_{\text{H}}$  5.18 ( $\delta_{\text{C}}$  91.1) with the quaternary carbonyl carbon C-9' ( $\delta_{\text{C}}$  167.6) and the  $^3J$ -HMBC correlation of H-2  $\delta_{\text{H}}$  5.18 ( $\delta_{\text{C}}$  73.7) with the carbonyl carbon C-9'' ( $\delta_{\text{C}}$  167.7) confirmed the location of the two *trans*-caffeic moieties at carbons C-1 and C-2 of the  $\alpha$ -L-rhamnopyranosyl moiety. Accordingly, compound 3 was identified as 1,2-di-*O-trans-p*-caffeoyl- $\alpha$ -L-rhamnopyranose.

The molecular formula of compound 4 was identical to that of compound 3 based on HRESIMS ( $\text{C}_{24}\text{H}_{25}\text{O}_{11}$ ). Similar to compound 2, the  $^1\text{H}$  and  $^{13}\text{C}$  NMR data of 4 showed two *trans*-caffeic acid moieties attached at C-1 and C-3 of the core  $\alpha$ -L-rhamnopyranose (Table 1, Fig. 2, and S18–S19<sup>†</sup>). This was

further confirmed through the HMBC experiment, which showed the  $^3J$ -HMBC correlation of the proton H-1  $\delta_{\text{H}}$  5.13 ( $\delta_{\text{C}}$  94.4) with the quaternary carbonyl carbon C-9' ( $\delta_{\text{C}}$  167.6) and the  $^3J$ -HMBC correlation of the proton H-3  $\delta_{\text{H}}$  5.24 ( $\delta_{\text{C}}$  74.1) with the carbonyl carbon C-9'' ( $\delta_{\text{C}}$  167.7) (Fig. 2). Accordingly, compound 4 was identified as 1,3-di-*O-trans-p*-caffeoyl- $\alpha$ -L-rhamnopyranose.

### 3.2. Biological activity

**3.2.1. Antiproliferative activity against MDA-MB-231 breast cancer cells.** The isolated compounds acylated rhamnopyranoses 1–4 (purity profile, Fig. S21–S24<sup>†</sup>), verbascoside 5 (purity profile, Fig. S25<sup>†</sup>), premnoside E–F 6–7, oleanolic acid 10, and maslinic acid 12 were screened for their ability to inhibit the HGF-induced proliferation of the c-Met-expressing highly invasive MDA-MB-231 breast cancer cells at 10  $\mu\text{M}$  using the MTT cell proliferation assay (Fig. 3(a)). HGF, a scatter factor, is the natural ligand for the activation of the c-Met receptor tyrosine kinase.<sup>11</sup> Results showed that 1,2-di-*O-trans-p*-coumaroyl- $\alpha$ -L-rhamnopyranose 1 was the most active. It inhibited 55% of the HGF-mediated cell proliferation of MDA-MB-231 cells. In an attempt to follow up this





dose-screening assay, the active compound **1** was tested at different doses against the same breast cancer MDA-MB-231 cells to calculate an  $IC_{50}$  value using the MTT assay (Fig. 3(b)). The olive phenolic secoiridoid *S*-(–)-oleocanthal with defined antiproliferative activity was used as a standard positive control at 10  $\mu$ M dose ( $IC_{50}$  15  $\mu$ M).<sup>33</sup> Compound **1** was able to inhibit the HGF-mediated cell proliferation in a dose-dependent manner, with an  $IC_{50}$  value of 17.3  $\mu$ M.

The isolated acylated rhamnopyranoses **1–4**, and verbascoside **5** were further screened for their antiproliferative activities against the breast cancer cell line MCF-7 and the normal cell line MCF-10A at 10  $\mu$ M using the MTT assay. Results showed that compound **1** had the highest activity against MCF-7 with an  $IC_{50}$  value of 4.95  $\mu$ M (similar to the standard staurosporine), with low activity on MCF-10A with an  $IC_{50}$  value of 17.35  $\mu$ M (Table 3). The other compounds **2–4** showed moderate activities against MCF-7 with  $IC_{50}$  values in the range of 11.09–20.04  $\mu$ M and moderate activities against MCF-10A.

Data were expressed as means  $\pm$  standard error of the mean (SEM) of at least three independent experiments. The differences among various treatment groups were determined by ANOVA followed by Dunnett's test using PASW Statistics® version 18 (Quarry Bay, Hong Kong). A difference of  $p < 0.05$  was considered statistically significant compared with a vehicle-treated control group. Staurosporine was used as a positive control.

**3.2.2. Antimigratory activity against the TNBC MDA-MB-231 cells.** Besides cell proliferation, the c-Met/HGF signaling axis plays an important role in cell motility and migration. Therefore, a 10  $\mu$ M treatment of each of the isolated compounds (acylated rhamnopyranoses **1–4**, verbascoside **5**, premnoside E-F **6–7**, oleanolic acid **10**, and maslinic acid **12**) were further tested in the wound healing scratch assay using the highly metastatic TNBC MDA-MB-231 cells. Mitogenic 40  $\mu$ g mL<sup>–1</sup> HGF was added to the media to induce cell migration *via* c-Met activation. The (–)-oleocanthal with defined anti-migratory activity ( $IC_{50}$  12  $\mu$ M) was used as a standard positive control.<sup>33</sup> 1,2-Di-*O*-*trans*-*p*-coumaroyl- $\alpha$ -L-rhamnopyranose **1** showed strong cell migration inhibitory activity and potently inhibited

Table 3 Antiproliferative activities of compounds **1–5**<sup>a</sup>

Compound	Cytotoxicity ( $IC_{50}$ $\mu$ M)	
	MCF-7	MCF-10A
<b>1</b>	4.95 $\pm$ 0.24	17.35 $\pm$ 0.86
<b>2</b>	11.09 $\pm$ 0.70	20.01 $\pm$ 0.34
<b>3</b>	17.07 $\pm$ 0.85	25.76 $\pm$ 1.28
<b>4</b>	20.04 $\pm$ 0.90	27.70 $\pm$ 1.10
<b>5</b>	10.45 $\pm$ 0.52	13.91 $\pm$ 0.69
Staurosporine	3.44 $\pm$ 0.17	11.42 $\pm$ 0.57

<sup>a</sup>  $IC_{50}$  = the concentration ( $\mu$ M) that caused a 50% inhibition of cell growth *in vitro*.

the HGF-induced cell migration, followed by triterpene oleanolic acid **10** (Fig. 4(a) and (b)).

**3.2.3. DPPH radical scavenging activity assay.** In this study, the electron donation ability of the free hydroxyl phenolic and/or carboxylic acid groups containing compounds (**1–7**, **10** and **12**) was screened using the DPPH scavenging activity assay (Fig. 5(a)). Results showed that compounds **1–5** were the most active with an  $IC_{50}$  value of 20.43  $\pm$  0.7, 20.43  $\pm$  0.5, 18.21  $\pm$  1.2, 18.21  $\pm$  1.0 and 17.50  $\pm$  1.3  $\mu$ g mL<sup>–1</sup>, respectively (Fig. 5(b)). The known potent scavenger L-ascorbic acid ( $IC_{50}$  10  $\pm$  0.3  $\mu$ g mL<sup>–1</sup>) was used as a positive control. This result might be associated with the free hydroxyl phenolic group for the active compounds, where the activity increased directly with increasing the number of the free hydroxyl group.<sup>23</sup>

**3.2.4. Pharmacophore model generation.** Pharmacophore modeling was an essential concept in rational drug design, which represented the notion that compounds were active/inactive at a specific receptor because they had/lacked some crucial functional groups (features) that correspondingly interacted with specific moieties in the binding site of the target receptor.<sup>22</sup> The pharmacophore modeling empowered the rational design of the more active ligands, discovered more active hits by screening molecular databases, generated 3D SAR, designed hits without the necessity of a receptor structure, and mapped the chemical space occupied by active ligands.<sup>22</sup> In the






Fig. 3 (a) Antiproliferative activity of compounds **1–7**, **10**, and **12** against the human TNBC MDA-MB-231 cells at 10  $\mu$ M screening doses using the MTT assay. (b) Dose–response effects of various compound **1** treatments on the viability of the TNBC MDA-MB-231 cells compared with the DMSO vehicle control. The viable cell count was determined using the MTT assay. Error bars show the SEM of  $N = 3$ /dose, \* $p < 0.05$  as compared with the vehicle-treated control groups. (–) Oleocanthal was used as a positive control at 10  $\mu$ M. # $p < 0.05$  as compared with the (–)-oleocanthal treated control group. The  $IC_{50}$  values are included for activity comparison.





(A)



(B)

Fig. 4 (a) Anti-migratory activity of compounds 1–7, 10 and 12 at 10  $\mu$ M against the human TNBC MDA-MB-231 cells using the wound-healing scratch assay. (b) Photomicrographs showing the migration inhibitory activity of compounds 1–7, 10 and 12 against the TNBC MDA-MB-231 cells in the wound healing assay, compared with DMSO as a vehicle control.




Fig. 5 (a) Antioxidant activity of compounds 1–7, 10, and 12 against DPPH at 40 µg mL<sup>-1</sup> screening doses using the DPPH radical scavenging activity assay. (b) Dose–response effects of various concentrations of compounds 1–5 treatments on the ability of the compounds to scavenge DPPH using the DPPH scavenging activities assay. (—) Ascorbic acid used as a positive control. The IC<sub>50</sub> values were included for activity comparison.



present study, the module of the Discovery Studio 2.5 software was applied to construct a pharmacophore hypothesis of the most active DPPH scavenging compounds 1–5 (acylated rhamnopyranoses 1–4, and verbascoside 5) (Fig. 6(a)). The highest-ranked model (generated using parameters described in the experimental part) had the following features: three HBAs, one HBD, one aromatic feature, and one Hyd. feature. The central HBA feature lies at a distance of 4.36 Å and 6.38 Å from the remaining two HBA features. Also, the HBD feature maintains a distance of 2.74 Å from the aromatic feature (Fig. 6(a)). The significant activity of the molecules can be explained by the importance of the HBA groups that function by the mechanism of single electron transfer followed by de-protonation.<sup>23</sup> Mapping of verbascoside 5, which has the most potent antioxidant activity with the developed pharmacophore, indicated that the hydroxyl group present in the aromatic ring and the phenyl ring constituted the HBDs and the aromatic features, respectively, that are critical for the antioxidant activity profile of the known natural antioxidant derivatives,<sup>23</sup> as the interaction of the electron-rich free radicals is captured by presenting the hydrophobic nature of the phenyl ring. Additionally, the carbonyl linked to the caffoyl nucleus constitutes an essential fragment, facilitating another HBA feature of the developed 3D pharmacophore model (Fig. 6(b)).

According to literature, and in general, plant-derived phenolic compounds have been shown to inhibit the initiation and progression of cancers by modulating the genes that regulate key processes, such as the oncogenic transformation of normal cells, growth and development of cancer, angiogenesis and metastasis.<sup>34</sup> Recent studies focused on identifying the

molecular basis for plant phenolic-induced cancer cell death have demonstrated the down regulation of oncogenic survival kinases such as phosphoinositide 3-kinase (PI<sub>3</sub>K) and protein kinase B (Akt); cell proliferation regulators that include extracellular signal-regulated kinase Erk1/2, D-type cyclins, and cyclin-dependent kinases (CDKs); transcription factors such as nuclear factor kappa beta (NF- $\kappa$ B), and nuclear factor erythroid 2 (NRF<sub>2</sub>); histone deacetylases HDAC<sub>1</sub> and HDAC<sub>2</sub>; and angiogenic factors vascular endothelial growth factor (VEGF), and fibroblast growth factor receptor 1 (FGFR<sub>1</sub>). Furthermore, while inhibiting oncogenic proteins, the phenolic compounds elevate the expression of tumor suppressor proteins P<sub>53</sub>, P<sub>21</sub>, and P<sub>27</sub>.<sup>34</sup> In addition, plant phenolic compounds modulate the levels of reactive oxygen species (ROS) in cells, thereby regulating cell proliferation, survival and apoptosis.<sup>34</sup>

Even though the phenolic compounds have been shown to exhibit anticancer activity, the efficacy varies from one compound to another due to the variations in their structures as well as their molecular targets. For example, the structure–activity-relationship (SAR) studies delineating the key functional groups required for exhibiting potent anticancer effects of phenolic compounds have identified the involvement of an aromatic ring and hydroxyl groups,<sup>35</sup> where compounds with a greater number of hydroxyl groups exhibited better activity compared to those with no hydroxyl groups or compounds with methoxy moieties. In addition, the presence of an unsaturated short fatty acid side chain also makes the phenolic compounds more potent.<sup>34</sup> Esters of aromatic acids are more potent when compared to the free versions.<sup>34–36</sup>




Fig. 6 (A) The highest-ranked pharmacophore model generated for compounds 1–5 showing the distances among the different features. Hydrogen bond acceptors (HBAs) are represented as yellow-vec-tored spheres, the hydrogen bond donor (HBD) is represented as a red-vec-tored sphere, ring aromatic features are represented as a violet-vec-tored sphere, and the hydrophobic group as a blue sphere. (B) Structure of the most active compound 5 and how it aligns the pharmacophore map. Exclusion spheres were hidden for clarity.



In this study, the antiproliferative and antimigratory activities for free hydroxyl phenolic and/or carboxylic acid groups containing compounds (acylated rhamnopyranoses **1–4**, verbascoside **5**, premnoside E-F **6–7**, oleanolic acid **10**, and maslinic acid **12**) were tested against the invasive human triple-negative breast cancer cells MDA-MB-231, MCF-7, and normal MCF-10A. Results showed that 1,2-di-*O-trans-p*-coumaroyl- $\alpha$ -L-rhamnopyranose **1** was able to inhibit the HGF-mediated cell proliferation in a dose-dependent manner, with an  $IC_{50}$  value of 17.74  $\mu$ M, MCF-7 with an  $IC_{50}$  value of 4.95  $\mu$ M, with low activity against MCF-10A with an  $IC_{50}$  value of 17.35  $\mu$ M using the MTT assay. On the other hand, compound **1** showed an antimigratory effect against the same cell line (Table 3, Fig. 3 and 4).

In response to the above biochemical parameters, the acylated rhamnopyranoses **1–4** contained two aromatic acid moieties attached to the  $\alpha$ -L-rhamnopyranoside in the ester form containing free phenolic hydroxyl groups and two unsaturated short fatty acid side chains. These features increased the antiproliferative and antimigratory activities of the acylated rhamnopyranoses compared to the other tested compounds (verbascoside **5**, premnoside E-F **6–7**, oleanolic acid **10**, and maslinic acid **12**) (Fig. 1).

Moreover, this study showed that the acylated rhamnopyranoside 1,2-di-*O-trans-p*-coumaroyl- $\alpha$ -L-rhamnopyranose **1** was the most active as an antiproliferative, antimigratory, and cytotoxic agent against MDA-MB-231 and MCF-7 compared to the other acylated rhamnopyranosides. Comparing this result with the previously reported acylated rhamnopyranose (1-*O-trans-p*-coumaroyl-2-*O-trans*-caffeoyl- $\alpha$ -L-rhamnopyranose) isolated from *P. odorata* leaves ( $IC_{50}$  12.9  $\mu$ M)<sup>11</sup> and the isolated tested hits **2**, **3**, **4** in the present work, a preliminary structure-activity relationship conclusion can be drawn by assuming the preference of the 1,2-di-aromatic acid substitution over the 1,3-disubstitution. Also, the *p*-coumaroyl with one C-4 OH group conferred better activity than that with the caffeoyl moiety (with the C-3 and C-4 dihydroxy/catechol system), showing that the lower number of -OH groups in the attached aromatic acids seemed better for the activity.

On the other hand, the radical scavenging activity of the free hydroxyl phenolic and/or carboxylic acid groups containing compounds (acylated rhamnopyranoses **1–4**, verbascoside **5**, premnoside E-F **6–7**, oleanolic acid **10**, and maslinic acid **12**) were tested using the stable radical DPPH assay. Results showed that the acylated rhamnopyranoses **1–4** and verbascoside **5** had the highest value of DPPH radical scavenging activities with an  $IC_{50}$  value range of 17.5–20.0  $\pm$  0.5  $\mu$ g mL<sup>-1</sup>, where verbascoside **5** was the most active compound. The pharmacophore model of the most active antioxidant compounds **1–5** was generated using MOE software, and showed three HBAs, one HBD, one aromatic ring, and one Hyd. group. The central HBA feature lies at a distance of 4.36 Å and 6.38 Å from the remaining two HBA features. Also, the HBD feature maintains a distance of 2.74 Å from the aromatic feature. The significant activity of compounds **1–5** can be explained by the importance of the HBA groups that function by the mechanism of single electron transfer followed by deprotonation. The mapping of verbascoside **5**, which has the

most potent antioxidant activity with the developed pharmacophore, indicated that the hydroxyl group present in the aromatic ring and the phenyl ring constituting the HBDs and the aromatic features, respectively, are critical for the antioxidant activity profile of the known natural antioxidant derivatives,<sup>23</sup> as the interaction of the electron-rich free radicals is captured by the hydrophobic nature of the phenyl ring. Additionally, the carbonyl linked to the caffeoyl nucleus constitutes an essential fragment, facilitating another HBA feature of the developed 3D pharmacophore model (Fig. 5–6).

As a result of the antiproliferative, antimigratory, cytotoxic, and antioxidants activities for the acylated 1,2-disubstituted  $\alpha$ -L-rhamnopyranoses, it could be considered another novel hit appropriate for further optimization for users to control breast cancer.

## 4. Conclusion

A phytochemical investigation of *P. odorata* young stems offered four new acylated rhamnopyranoses **1–4**, along with fourteen known compounds. This study confirmed the antiproliferative, antimigratory and cytotoxic potential of the acylated rhamnopyranoses against the human TNBC MDA-MB-231, MCF-7, and MCF-10A. 1,2-di-*O-trans-p*-coumaroyl- $\alpha$ -L-rhamnopyranose **1** was able to inhibit the HGF-mediated cell proliferation in a dose-dependent manner, with an  $IC_{50}$  value of 17.74  $\mu$ M compared with (–)-oleocanthal as the positive control ( $IC_{50}$  15  $\mu$ M). On the other hand, compound **1** showed an antimigratory effect against the same cell line at 10  $\mu$ M concentrations. Furthermore, compound **1** showed cytotoxic activity against MCF-7 with an  $IC_{50}$  value of 4.95  $\mu$ M, and showed low cytotoxic activity on the MCF-10A cell line with an  $IC_{50}$  value of 17.35  $\mu$ M using the MTT assay. Additionally, acylated rhamnopyranoses **1–4** and verbascoside **5** showed the highest potential of DPPH radical scavenging activities with an  $IC_{50}$  value range of 17.5–20.0  $\pm$  0.5  $\mu$ g mL<sup>-1</sup>. The pharmacophore model generated using Molecular Operating Environment (MOE) for compounds **1–5** showed three hydrogen bond acceptors (HBAs), one hydrogen bond donor (HBDs), one aromatic ring (Aro), and one hydrophobic (Hyd.) group. The central HBA feature lies at a distance of 4.36 Å and 6.38 Å from the remaining two HBA features. Also, the HBD feature maintains a distance of 2.74 Å from the aromatic feature. Acylated rhamnopyranose **1** can be considered a good scaffold for developing new anti-breast cancer compounds. In the light of the previous findings, it is worth mentioning that *P. odorata* produced a minor amount of the acylated rhamnopyranose. On the other hand, the organic solvent consumption does not favor the commercialized production of the rhamnopyranoses. Consequently, further synthesis and/or compound optimization for the active hits can be considered a great way to commercialize this class of compounds.

## Conflicts of interest

The authors declare no conflict of interest.



## References

- 1 J. Ferlay, M. Colombet, I. Soerjomataram, C. Mathers, D. Parkin, M. Piñeros, A. Znaor and F. Bray, Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, *Int. J. Cancer*, 2019, **144**, 1941–1953, DOI: 10.1002/ijc.31937.
- 2 F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre and A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, *Ca-Cancer J. Clin.*, 2018, **68**, 394–424, DOI: 10.3322/caac.21492.
- 3 R. L. Siegel, K. D. Miller and A. Jemal, Cancer statistics, 2019, *Ca-Cancer J. Clin.*, 2019, **69**, 7–34, DOI: 10.3322/caac.21551.
- 4 E. Giovannucci, D. M. Harlan, M. C. Archer, R. M. Bergenstal, S. M. Gapstur, L. A. Habel, M. Pollak, J. G. Regensteiner and D. Yee, Diabetes and cancer: a consensus report, *Ca-Cancer J. Clin.*, 2010, **60**, 207–221, DOI: 10.3322/caac.20078.
- 5 E. Birben, U. M. Sahiner, C. Sackesen, S. Erzurum and O. Kalayci, Oxidative stress and antioxidant defense, *World Allergy Organ. J.*, 2012, **5**, 9–19.
- 6 N. Noda and H. Wakasugi, Cancer and oxidative stress, *Japan Med. Assoc. J.*, 2001, **44**, 535–539.
- 7 M. Leporini, G. Catinella, M. Bruno, T. Falco, R. Tundis and M. R. Loizzo, Investigating the Antiproliferative and Antioxidant Properties of *Pancreaticum maritimum* L. (Amaryllidaceae) Stems, Flowers, Bulbs, and Fruits Extracts, *J. Evidence-Based Complementary Altern. Med.*, 2018, **2018**, 1–8.
- 8 N. Sharma, A. Sharma, G. Bhatia, M. Landi, M. Brestic, B. Singh, J. Singh, S. Kaur and R. Bhardwaj, Isolation of phytochemicals from *Bauhinia variegata* L. Bark and their *in vitro* antioxidant and cytotoxic potential, *Antioxidants*, 2019, **8**, 492.
- 9 A. Puttisri, A. Pamarapa, M. Jayanton Patumanond, M. Apichat Tantraworasin and C. Charoentum, Recurrence and death from breast cancer after complete treatments: An experience from hospitals in Northern Thailand, *J. Med. Assoc. Thailand*, 2014, **97**, 932–938.
- 10 G. Suresh, K. S. Babu, V. R. S. Rao, M. S. A. Rao, V. L. Nayak and S. Ramakrishna, Novel cytotoxic icetexane diterpenes from *Premna latifolia* Roxb, *Tetrahedron Lett.*, 2011, **52**, 1273–1276.
- 11 A. H. Elmaidomy, M. M. Mohyeldin, M. M. Ibrahim, H. M. Hassan, E. Amin, M. E. Rateb, M. H. Hetta and K. A. El Sayed, Acylated Iridoids and Rhamnopyranoses from *Premna odorata* (Lamiaceae) as Novel Mesenchymal–Epithelial Transition Factor Receptor Inhibitors for the Control of Breast Cancer, *Phytother. Res.*, 2017, **31**, 1546–1556, DOI: 10.1002/ptr.5882.
- 12 P. S. Ghosh, N. Das and B. Dinda, Antioxidant flavone glycosides and other constituents from *Premna latifolia* leaves, *Indian J. Chem.*, 2014, **53B**, 746–749.
- 13 D. Yadav, N. Masood, S. Luqman, P. Brindha and M. M. Gupta, Antioxidant furofuran lignans from *Premna integrifolia*, *Ind. Crops Prod.*, 2013, **41**, 397–402.
- 14 S. Habtemariam and G. K. Varghese, A Novel Diterpene Skeleton: Identification of a highly aromatic, cytotoxic and antioxidant 5-methyl-10-demethyl-abietane-type diterpene from *Premna serratifolia*, *Phytother. Res.*, 2015, **29**, 80–85, DOI: 10.1002/ptr.5229.
- 15 A. Hymavathi, K. S. Babu, V. Naidu, S. R. Krishna, P. V. Diwan and J. M. Rao, Bioactivity-guided isolation of cytotoxic constituents from stem–bark of *Premna tomentosa*, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 5727–5731.
- 16 G. Suresh, K. S. Babu, M. S. A. Rao, V. R. S. Rao, P. A. Yadav, V. L. Nayak and S. Ramakrishna, Premnalatifolin A, a novel dimeric diterpene from *Premna latifolia* Roxb, *Tetrahedron Lett.*, 2011, **52**, 5016–5019.
- 17 E. Stahl, *Thin Layer Chromatography*, Springer Verlage, Berlin, Heidelberg, New York, 2nd, 1970, p. 810, DOI: 10.1002/star.19700221110.
- 18 D. L. Holliday and V. Speirs, Choosing the right cell line for breast cancer research, *Breast Cancer Res.*, 2011, **13**, 215.
- 19 M. M. Mohyeldin, M. R. Akl, H. Y. Ebrahim, A. M. Dragoi, S. Dykes, J. A. Cardelli and K. A. El Sayed, The oleocanthol-based homovanillyl sinapate as a novel c-Met inhibitor, *Oncotarget*, 2016, **7**, 32247.
- 20 A. H. Elmaidomy, R. Mohammed, H. M. Hassan, A. I. Owis, M. E. Rateb, M. A. Khanfar, M. Krischke, M. J. Mueller and U. R. Abdelmohsen, Metabolomic Profiling and Cytotoxic Tetrahydrofurofuran Lignans Investigations from *Premna odorata* Blanco, *Metabolites*, 2019, **9**, 223.
- 21 M. R. Loizzo, M. B. Jemia, F. Senatore, M. Bruno, F. Menichini and R. Tundis, Chemistry and functional properties in prevention of neurodegenerative disorders of five Cistus species essential oils, *Food Chem. Toxicol.*, 2013, **59**, 586–594.
- 22 M. A. Khanfar, M. M. AbuKhader, S. Alqtaishat and M. O. Taha, Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol, glyburide, metipranolol, sulfamethizole, glipizide, and pioglitazone, *J. Mol. Graphics Modell.*, 2013, **42**, 39–49.
- 23 I. Mitra, A. Saha and K. Roy, Predictive modeling of antioxidant coumarin derivatives using multiple approaches: descriptor-based QSAR, 3D-pharmacophore mapping, and HQSAR, *Sci. Pharm.*, 2013, **81**, 57–80.
- 24 T. Kanchanapoom, R. Kasai and K. Yamasaki, Phenolic glycosides from *Barnettia kerrii*, *Phytochem.*, 2002, **59**, 565–570.
- 25 M. A. Hossain and Z. Ismail, Isolation and characterization of triterpenes from the leaves of *Orthosiphon stamineus*, *Arabian J. Chem.*, 2013, **6**, 295–298.
- 26 T. B. Ayeleso, M. G. Matumba and E. Mukwevho, Oleanolic acid and its derivatives: biological activities and therapeutic potential in chronic diseases, *Molecules*, 2017, **22**, 1915.
- 27 L. H. Vázquez, J. Palazon and A. Navarro-Ocaña, The Pentacyclic Triterpenes  $\alpha$ -,  $\beta$ -amyrins: A Review of Sources and Biological Activities, *Phytochem.*, 2012, **5**, 1–5.
- 28 L. L. Pierre and M. N. Moses, Isolation and characterisation of stigmasterol and  $\beta$ -sitosterol from *Odontonema strictum* (acanthaceae), *J. Innovations Pharm. Biol. Sci.*, 2015, **2**, 88–96.



- 29 S. Moradkhani, F. Kobarfard and S. A. M. Ayatollahi, Phytochemical investigations on chemical constituents of *Achillea tenuifolia* Lam, *Iran J. Pharm. Res.*, 2014, **13**, 1049.
- 30 I. S. Lee, S. R. Oh, K. Y. Jung, D. S. Kim, J. H. Kim and H. K. Lee, Anticomplementary activity and complete <sup>13</sup>C NMR assignment of citrostadienol from *Schizandra chinensis*, *Intern. J. Pharmacogn.*, 1997, **35**, 358–363, DOI: 10.1080/09251619708951283.
- 31 J. Bulama, S. Dangoggo, M. Halilu, A. Tsaf and S. Hassan, Isolation and characterization of palmitic acid from ethyl acetate extract of root bark of *Terminalia glaucescens*, *J. Chem. Mater. Res.*, 2014, **6**, 140–143.
- 32 M. Wen, *Chemical analysis and biosynthesis of secondary alcohols in plant cuticular waxes*, University of British Columbia, 2009.
- 33 M. R. Akl, N. M. Ayoub, M. M. Mohyeldin, B. A. Busnena, A. I. Foudah, Y.-Y. Liu and K. A. E. Sayed, Olive phenolics as c-Met inhibitors:(-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models, *PLoS One*, 2014, **9**, e97622.
- 34 P. G. Anantharaju, P. C. Gowda, M. G. Vimalambike and S. V. Madhunapantula, An overview on the role of dietary phenolics for the treatment of cancers, *Nutr. J.*, 2016, **15**, 99.
- 35 Y.-J. Lee, P.-H. Liao, W.-K. Chen and C.-C. Yang, Preferential cytotoxicity of caffeic acid phenethyl ester analogues on oral cancer cells, *Cancer Lett.*, 2000, **153**, 51–56.
- 36 M. Chen, H. Meng, Y. Zhao, F. Chen and S. Yu, Antioxidant and in vitro anticancer activities of phenolics isolated from sugar beet molasses, *BMC Complementary Altern. Med.*, 2015, **15**, 313.

